Research programme: targeted gene therapy - AAVP Biosystems

Drug Profile

Research programme: targeted gene therapy - AAVP Biosystems

Alternative Names: RGD AAVP TNF

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AAVP Biosystems
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Feb 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 09 Feb 2017 AAVP Biosystems announces intention to submit IND applications to US FDA
  • 09 Feb 2017 AAVP Biosystems plans a phase I trial for Cancer (Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top